Robert Bessler Sells 1,701 Shares of LifeStance Health Group (NASDAQ:LFST) Stock

LifeStance Health Group, Inc. (NASDAQ:LFST) Director Robert Bessler sold 1,701 shares of LifeStance Health Group stock in a transaction that occurred on Monday, December 22nd. The shares were sold at an average price of $7.04, for a total transaction of $11,975.04. Following the sale, the director owned 1,318,133 shares of the company’s stock, valued at approximately $9,279,656.32. The trade was a 0.13% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this link.

Robert Bessler also recently made the following trade(s):

• On Friday, December 19th, Robert Bessler sold 119,942 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.04, for a total transaction of $844,391.68.
• On Thursday, December 18th, Robert Bessler sold 6,442 shares of LifeStance Health Group stock. The stock was sold at an average price of $7.00, for a total transaction of $45,094.00.
• On Monday, December 15th, Robert Bessler sold 12,371 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.00, for a total transaction of $86,597.00.
• On Friday, December 12th, Robert Bessler sold 79,630 shares of LifeStance Health Group stock. The shares were sold at an average price of $7.01, for a total transaction of $558,206.30.

LifeStance Health Group Stock Performance

NASDAQ LFST opened at $7.10 on Thursday. The stock has a 50-day simple moving average of $6.11 and a two-hundred day simple moving average of $5.39. The firm has a market capitalization of $2.76 billion, a P/E ratio of -236.50 and a beta of 1.13. LifeStance Health Group, Inc. has a fifty-two week low of $3.74 and a fifty-two week high of $8.30. The company has a debt-to-equity ratio of 0.18, a quick ratio of 1.58 and a current ratio of 1.58.

LifeStance Health Group (NASDAQ:LFST) last issued its earnings results on Wednesday, November 5th. The company reported $0.02 EPS for the quarter, topping analysts’ consensus estimates of ($0.01) by $0.03. The firm had revenue of $363.81 million for the quarter, compared to the consensus estimate of $355.06 million. LifeStance Health Group had a negative return on equity of 0.62% and a negative net margin of 0.67%.The company’s revenue was up 16.3% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.02) earnings per share. On average, equities analysts forecast that LifeStance Health Group, Inc. will post -0.18 earnings per share for the current year.

Institutional Inflows and Outflows

Several hedge funds have recently modified their holdings of the stock. Park Edge Advisors LLC acquired a new stake in LifeStance Health Group in the 2nd quarter worth about $52,000. Bayesian Capital Management LP acquired a new position in shares of LifeStance Health Group during the second quarter valued at approximately $52,000. Public Employees Retirement System of Ohio purchased a new position in shares of LifeStance Health Group in the second quarter valued at approximately $70,000. Blair William & Co. IL acquired a new stake in shares of LifeStance Health Group in the second quarter worth approximately $70,000. Finally, Vanguard Personalized Indexing Management LLC acquired a new stake in shares of LifeStance Health Group in the third quarter worth approximately $72,000. Institutional investors and hedge funds own 85.50% of the company’s stock.

Analysts Set New Price Targets

Several research firms recently issued reports on LFST. BTIG Research boosted their target price on shares of LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research note on Friday, December 12th. Wall Street Zen downgraded shares of LifeStance Health Group from a “buy” rating to a “hold” rating in a research report on Saturday, October 11th. UBS Group raised their target price on LifeStance Health Group from $9.00 to $10.00 and gave the company a “buy” rating in a research report on Friday, November 7th. BMO Capital Markets began coverage on LifeStance Health Group in a research note on Thursday, November 13th. They issued an “outperform” rating and a $8.00 price target for the company. Finally, Zacks Research downgraded LifeStance Health Group from a “strong-buy” rating to a “hold” rating in a research report on Wednesday, November 5th. Two investment analysts have rated the stock with a Strong Buy rating, five have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company has an average rating of “Moderate Buy” and a consensus target price of $8.83.

About LifeStance Health Group

LifeStance Health Group (NASDAQ:LFST) is a leading provider of outpatient mental health services in the United States. Headquartered in New York City, the company operates a growing network of clinics that deliver integrated, patient-centered psychological and psychiatric care. LifeStance’s mission is to expand access to high-quality mental health treatment by combining evidence-based therapy modalities with personalized treatment plans.

The company’s service offerings include individual, family, and group psychotherapy, psychiatric medication management, psychological assessment, and telehealth services.